Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review
et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100776, Oct 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Meta analysis of 43 studies reporting: "HCQ was found consistently effective against COVID-19 when used early, in the outpatient setting. It was found overall effective also including inpatient studies. No unbiased study found worse outcomes with HCQ use. No mortality or serious safety adverse event was found."
9 meta analyses show significant improvements with hydroxychloroquine for mortality31-34,
hospitalization31,
recovery35,
combined death/hospitalization/cases36,
cases37,38, and
viral clearance39.
Currently there are 38 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [61‑85%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
29.
Colson et al., Chloroquine and Hydroxychloroquine as Available Weapons to Fight COVID-19, Int J. Antimicrob Agents, doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4., www.ncbi.nlm.nih.gov/pmc/articles/PMC7135139/.
30.
Al-Bari, M., Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacology Research & Perspectives, doi:10.1002/prp2.293.
31.
Landsteiner de Sampaio Amêndola et al., COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis, Journal of Clinical Medicine, doi:10.3390/jcm11226865.
32.
Risch, H., Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis, American Journal of Epidemiology, kwaa093, 27 May 2020, doi:10.1093/aje/kwaa093.
33.
Risch (B), H., Response to: “Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients” and “Re: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis”, American Journal of Epidemiology, July 20, 2020, doi:10.1093/aje/kwaa152.
34.
Stricker et al., Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis, Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.001.
35.
Prodromos et al., Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review, New Microbes and New Infections, doi:10.1016/j.nmni.2020.100776.
36.
Ladapo et al., Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis, medRxiv, doi:10.1101/2020.09.30.20204693.
37.
García-Albéniz et al., Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19, European Journal of Epidemiology, doi:10.1007/s10654-022-00891-4.
Prodromos et al., 5 Oct 2020, peer-reviewed, 2 authors.
Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
doi:10.1016/j.nmni.2020.100776
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies. We hypothesized that a systematic review would show HCQ to be effective against COVID-19, more effective when provided earlier, not associated with worsening disease and safe. We searched PubMed, Cochrane, Embase, Google Scholar and Google for all reports on HCQ as a treatment for COVID-19 patients. This included preprints and preliminary reports on larger COVID-19 studies. We examined the studies for efficacy, time of administration and safety. HCQ was found to be consistently effective against COVID-19 when provided early in the outpatient setting. It was also found to be overall effective in inpatient studies. No unbiased study found worse outcomes with HCQ use. No mortality or serious safety adverse events were found. HCQ is consistently effective against COVID-19 when provided early in the outpatient setting, it is overall effective against COVID-19, it has not produced worsening of disease and it is safe.
Conflict of interest None declared.
References
Ada, Tavelli, Bai, Marchetti, Cozzi-Lepri, Effectiveness of hydroxychloroquine in COVID-19 disease: a done and dusted situation?, Int J Infect Dis
Ahmad, Alam, Saadi, Mahmud, Saadi, Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities, medRxiv
An, Kim, Kim, Kang, Kimn et al., Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea, medRxiv
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Ashraf, Shokouhi, Shirali, Davari-Tanha, Memar et al., COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Bernaola, Mena, Bernaola, Lara, Carballo et al., Observational study of the efficiency of treatments in patients hospitalized with Covid-19 in
Carlucci, Ahuja, Petrilli, Rajagopalan, Jones et al., Hydroxychloroquine and azithromycin plus zinc vs. hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv
Cavalcanti, Zampieri, Azevedo, Rosa, Avezum et al., infection (COVID-19): rationale and design of a randomised, controlled clinical trial
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv
Davido, Boussaid, Vaugier, Lansaman, Bouchand et al., Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time, Int J Antimicrob Agents
De Novales, Ramírez-Olivencia, Estébanez, De Dios, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study, Preprints, doi:10.20944/preprints202005.0057.v1
Drugs, Hydroxychloroquine prices, coupons, and patient assistance programs
Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A
Esper, Da Silva, Oikawa, Castro, Razuk-Filho, Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gautret, Lagier, Parola, Meddeb, Sevestre et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Giacomelli, Pagani, Ridolfo, Oreni, Conti et al., Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study, medRxiv
Gumbien, Fox, Two coronavirus studies retracted after questions emerge about data, CNN
Guérin, Lévy, Thomas, Lardenois, Lacrosse et al., Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19, Asian J Med Health
Horby, Mafham, Linsell, Bell, Staplin et al., Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial, medRxiv
Ip, Berry, Hansen, Goy, Pecora et al., Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study, medRxiv
Kalligeros, Shehadeh, Atalla, Mylona, Aung et al., Hydroxychloroquine use in hospitalized patients with COVID-19: an observational matched cohort study, J Glob Antimicrob Resist
Kim, Jang, Park, Kim, Hwang et al., Treatment response to hydroxychloroquine, lopinavir/ritonavir, and antibiotics for moderate COVID 19: a first report on the pharmacological outcomes from South Korea, medRxiv
Kim, Kim, Kwon, Jung, Kim et al., Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease, Korean J Intern Med
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis
Lopez, Duclos, Pastene, Bezulier, Guilhaumou et al., Effects of hydroxychloroquine on Covid-19 in intensive care unit patients: preliminary results, Int J Antimicrob Agents
Lupkin, Remdesivir priced at more than $3,100 for a course of treatment, NPR
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, Med
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv
Mallat, Hamed, Balkis, Mohamed, Mooty et al., Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study, medRxiv
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Mitjà, Corbacho-Monné, Ubals, Tebe, Peñafiel et al., Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized-controlled trial, Clin Infect Dis
Molina, Delaugerre, Goffj, Lima, Ponscarme et al., No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect
Nmni Prodromos, Rumschlag HCQ in COVID-19
Nmni Prodromos, Rumschlag HCQ in COVID-19
Paccoud, Tubach, Baptiste, Bleibtreu, Hajage et al., Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital, Clin Infect Dis
Prodromos, Hydroxychloroquine is protective to the heart, not harmful: a systematic review, New Microbe. New Infect
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with Covid-19-preliminary report, N Engl J Med
Rivera, Peters, Panagiotou, Shah, Kuderer et al., Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study, Cancer Discov
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Sbidian, Josse, Lemaitre, Mayer, Bernaux et al., Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Scholz, Derwand, Zelenko, COVID-19 outpatients-early riskstratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study, Preprints, doi:10.20944/preprints202007.0025.v1
Singh, Khan, Chowdhry, Chatterjee, Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-real-world evidence from a federated electronic medical record network, medRxiv
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial, Ann Intern Med
Spinner, Gottlieb, Criner, López, Cattelan et al., Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Xue, Liu, Luo, Liu, Qiu et al., Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China, J Med Virol
Yu, Li, Chen, Li, Jiang et al., Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs, Sci China Life Sci
Yu, Li, Chen, Zhou, Wang et al., Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19, Sci China Life Sci
Zelenko, Open letter describing Covid-19 treatment protocol
DOI record:
{
"DOI": "10.1016/j.nmni.2020.100776",
"ISSN": [
"2052-2975"
],
"URL": "http://dx.doi.org/10.1016/j.nmni.2020.100776",
"alternative-id": [
"S2052297520301281"
],
"article-number": "100776",
"author": [
{
"affiliation": [],
"family": "Prodromos",
"given": "C.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Rumschlag",
"given": "T.",
"sequence": "additional"
}
],
"container-title": "New Microbes and New Infections",
"container-title-short": "New Microbes and New Infections",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
10,
5
]
],
"date-time": "2020-10-05T16:35:01Z",
"timestamp": 1601915701000
},
"deposited": {
"date-parts": [
[
2020,
12,
25
]
],
"date-time": "2020-12-25T23:33:02Z",
"timestamp": 1608939182000
},
"indexed": {
"date-parts": [
[
2024,
5,
3
]
],
"date-time": "2024-05-03T11:48:53Z",
"timestamp": 1714736933573
},
"is-referenced-by-count": 22,
"issued": {
"date-parts": [
[
2020,
11
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
11,
1
]
],
"date-time": "2020-11-01T00:00:00Z",
"timestamp": 1604188800000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
10,
3
]
],
"date-time": "2020-10-03T00:00:00Z",
"timestamp": 1601683200000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297520301281?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297520301281?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "100776",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
11
]
]
},
"published-print": {
"date-parts": [
[
2020,
11
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"article-title": "Effectiveness of hydroxychloroquine in COVID-19 disease: a done and dusted situation?",
"author": "Monforte",
"journal-title": "Int J Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib1",
"year": "2020"
},
{
"DOI": "10.9734/ajmah/2020/v18i730224",
"article-title": "Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19",
"author": "Guérin",
"doi-asserted-by": "crossref",
"first-page": "45",
"journal-title": "Asian J Med Health",
"key": "10.1016/j.nmni.2020.100776_bib2",
"volume": "18",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study",
"author": "Mallat",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib3",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial",
"author": "Cavalcanti",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib4",
"year": "2020"
},
{
"author": "Zelenko",
"key": "10.1016/j.nmni.2020.100776_bib5",
"series-title": "Open letter describing Covid-19 treatment protocol",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101738",
"article-title": "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France",
"author": "Million",
"doi-asserted-by": "crossref",
"journal-title": "Travel Med Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib6",
"year": "2020"
},
{
"author": "Gumbien",
"key": "10.1016/j.nmni.2020.100776_bib7",
"series-title": "Two coronavirus studies retracted after questions emerge about data",
"year": "2020"
},
{
"author": "Esper",
"key": "10.1016/j.nmni.2020.100776_bib8",
"series-title": "Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized–controlled trial",
"author": "Mitjà",
"journal-title": "Clin Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib9",
"year": "2020"
},
{
"DOI": "10.7326/M20-4207",
"article-title": "Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial",
"author": "Skipper",
"doi-asserted-by": "crossref",
"journal-title": "Ann Intern Med",
"key": "10.1016/j.nmni.2020.100776_bib10",
"year": "2020"
},
{
"article-title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial",
"author": "Chen",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib11",
"year": "2020"
},
{
"DOI": "10.1016/j.ijid.2020.06.099",
"article-title": "Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",
"author": "Arshad",
"doi-asserted-by": "crossref",
"journal-title": "Int J Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib12",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.106129",
"article-title": "Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time",
"author": "Davido",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.nmni.2020.100776_bib13",
"year": "2020"
},
{
"DOI": "10.1002/jmv.26193",
"article-title": "Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China",
"author": "Xue",
"doi-asserted-by": "crossref",
"journal-title": "J Med Virol",
"key": "10.1016/j.nmni.2020.100776_bib14",
"year": "2020"
},
{
"DOI": "10.1093/cid/ciaa791",
"article-title": "Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital",
"author": "Paccoud",
"doi-asserted-by": "crossref",
"journal-title": "Clin Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib15",
"year": "2020"
},
{
"article-title": "No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial",
"author": "Mahevas",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib16",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2012410",
"article-title": "Observational study of hydroxychloroquine in hospitalized patients with Covid-19",
"author": "Geleris",
"doi-asserted-by": "crossref",
"journal-title": "N Engl J Med",
"key": "10.1016/j.nmni.2020.100776_bib17",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.8630",
"article-title": "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State",
"author": "Rosenberg",
"doi-asserted-by": "crossref",
"journal-title": "JAMA",
"key": "10.1016/j.nmni.2020.100776_bib18",
"year": "2020"
},
{
"DOI": "10.1007/s11427-020-1782-1",
"article-title": "Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs",
"author": "Yu",
"doi-asserted-by": "crossref",
"journal-title": "Sci China Life Sci",
"key": "10.1016/j.nmni.2020.100776_bib19",
"year": "2020"
},
{
"article-title": "Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19",
"author": "Yu",
"journal-title": "Sci China Life Sci",
"key": "10.1016/j.nmni.2020.100776_bib20",
"year": "2020"
},
{
"article-title": "Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea",
"author": "An",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib21",
"year": "2020"
},
{
"article-title": "Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial",
"author": "Horby",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib22",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.106136",
"article-title": "Effects of hydroxychloroquine on Covid-19 in intensive care unit patients: preliminary results",
"author": "Lopez",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.nmni.2020.100776_bib23",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—an observational study",
"author": "Ip",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib24",
"year": "2020"
},
{
"article-title": "Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States—real-world evidence from a federated electronic medical record network",
"author": "Singh",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib25",
"year": "2020"
},
{
"author": "Magagnoli",
"key": "10.1016/j.nmni.2020.100776_bib26",
"series-title": "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med (N Y)",
"year": "2020"
},
{
"DOI": "10.1158/2159-8290.CD-20-0941",
"article-title": "Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study",
"author": "Rivera",
"doi-asserted-by": "crossref",
"journal-title": "Cancer Discov",
"key": "10.1016/j.nmni.2020.100776_bib27",
"year": "2020"
},
{
"article-title": "Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities",
"author": "Ahmad",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib28",
"year": "2020"
},
{
"article-title": "COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes",
"author": "Ashraf",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib29",
"year": "2020"
},
{
"article-title": "Observational study of the efficiency of treatments in patients hospitalized with Covid-19 in Madrid",
"author": "Bernaola",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib30",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine and azithromycin plus zinc vs. hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients",
"author": "Carlucci",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib31",
"year": "2020"
},
{
"article-title": "Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study",
"author": "de Novales",
"journal-title": "Preprints",
"key": "10.1016/j.nmni.2020.100776_bib32",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"author": "Gautret",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.nmni.2020.100776_bib33",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101663",
"article-title": "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study",
"author": "Gautret",
"doi-asserted-by": "crossref",
"journal-title": "Travel Med Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib34",
"year": "2020"
},
{
"article-title": "Lopinavir–ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease, 2019",
"author": "Kim",
"journal-title": "Korean J Intern Med",
"key": "10.1016/j.nmni.2020.100776_bib35",
"year": "2020"
},
{
"article-title": "Treatment response to hydroxychloroquine, lopinavir/ritonavir, and antibiotics for moderate COVID 19: a first report on the pharmacological outcomes from South Korea",
"author": "Kim",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib36",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101791",
"article-title": "Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis",
"author": "Lagier",
"doi-asserted-by": "crossref",
"journal-title": "Travel Med Infect Dis",
"key": "10.1016/j.nmni.2020.100776_bib37",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France",
"author": "Sbidian",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib38",
"year": "2020"
},
{
"author": "Scholz",
"key": "10.1016/j.nmni.2020.100776_bib39",
"series-title": "COVID-19 outpatients—early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study. Preprints",
"year": "2020"
},
{
"article-title": "Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study",
"author": "Giacomelli",
"journal-title": "medRxiv",
"key": "10.1016/j.nmni.2020.100776_bib40",
"year": "2020"
},
{
"DOI": "10.1016/j.jgar.2020.07.018",
"article-title": "Hydroxychloroquine use in hospitalized patients with COVID-19: an observational matched cohort study",
"author": "Kalligeros",
"doi-asserted-by": "crossref",
"journal-title": "J Glob Antimicrob Resist",
"key": "10.1016/j.nmni.2020.100776_bib41",
"year": "2020"
},
{
"DOI": "10.1016/j.medmal.2020.03.006",
"article-title": "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection",
"author": "Molina",
"doi-asserted-by": "crossref",
"first-page": "30085",
"journal-title": "Med Mal Infect",
"key": "10.1016/j.nmni.2020.100776_bib42",
"volume": "50",
"year": "2020"
},
{
"key": "10.1016/j.nmni.2020.100776_bib43",
"series-title": "NIH halts clinical trial of hydroxychloroquine",
"year": "2020"
},
{
"DOI": "10.1136/bmj.m1849",
"article-title": "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial",
"author": "Tang",
"doi-asserted-by": "crossref",
"first-page": "m1849",
"journal-title": "BMJ",
"key": "10.1016/j.nmni.2020.100776_bib44",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1016/j.nmni.2020.100747",
"article-title": "Hydroxychloroquine is protective to the heart, not harmful: a systematic review",
"author": "Prodromos",
"doi-asserted-by": "crossref",
"journal-title": "New Microbe. New Infect",
"key": "10.1016/j.nmni.2020.100776_bib45",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.16349",
"article-title": "Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial",
"author": "Spinner",
"doi-asserted-by": "crossref",
"journal-title": "JAMA",
"key": "10.1016/j.nmni.2020.100776_bib46",
"year": "2020"
},
{
"article-title": "Dexamethasone in hospitalized patients with Covid-19—preliminary report",
"author": "Horby",
"journal-title": "N Engl J Med",
"key": "10.1016/j.nmni.2020.100776_bib47",
"year": "2020"
},
{
"DOI": "10.1073/pnas.2004168117",
"article-title": "Effectiveness of convalescent plasma therapy in severe COVID-19 patients",
"author": "Duan",
"doi-asserted-by": "crossref",
"first-page": "9490",
"journal-title": "Proc Natl Acad Sci U S A",
"key": "10.1016/j.nmni.2020.100776_bib48",
"volume": "117",
"year": "2020"
},
{
"author": "Drugs.com",
"key": "10.1016/j.nmni.2020.100776_bib49"
},
{
"author": "Lupkin",
"key": "10.1016/j.nmni.2020.100776_bib50",
"series-title": "Remdesivir priced at more than $3,100 for a course of treatment",
"year": "2020"
}
],
"reference-count": 50,
"references-count": 50,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S2052297520301281"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review",
"type": "journal-article",
"volume": "38"
}
